Skip to Main content Skip to Navigation
Journal articles

The Challenge of COVID-19 and Hematopoietic Cell Transplantation; EBMT Recommendations for Management of Hematopoietic Cell Transplant Recipients, Their Donors, and Patients Undergoing CAR T-cell Therapy

Per Ljungman 1, 2, * Malgorzata Mikulska 3 Rafael de la Camara 4 Grzegorz Basak 5 Christian Chabannon 6, 7 Selim Corbacioglu 8 Rafael Duarte 9 Harry Dolstra 10 Arjan Lankester 11 Mohamad Mohty 12 Silvia Montoto 13 John Murray 14 Régis Peffault de Latour 15 John Snowden 16 Ibrahim Yakoub-Agha 17, 18 Bregje Verhouven 11 Nicolaus Kröger 19 Jan Styczynski 20
* Corresponding author
1 Karolinska University Hospital [Stockholm]
2 Karolinska Institutet [Stockholm]
3 UNIGE - University of Genoa
4 Hospital de la Princesa [Madrid, Espagne]
5 Medical University of Warsaw - Poland
6 Institut Paoli-Calmettes
7 Centre d'Investigations Cliniques en Biothérapies [Marseille]
8 UR - Universität Regensburg
9 Hospital Universitario Puerta de Hierro [Madrid, Espagne]
10 Radboud University Medical Center [Nijmegen]
11 Leiden University Medical Center (LUMC)
12 Department of Hematology [Paris]
13 Barts Health NHS Trust [London, UK]
14 The Christie NHS Foundation Trust [Manchester, Royaume-Uni]
15 BMT Unit [Paris]
Department of Hematology [Paris]
16 Sheffield Teaching Hospitals NHS Foundation Trust [Sheffield, Royaume-Uni]
17 CHRU Lille - Centre Hospitalier Régional Universitaire [Lille]
18 Université de Lille
19 UKE - Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg]
20 Nicolaus Copernicus University [Toruń]
Abstract : The new coronavirus SARS-CoV-2 has rapidly spread over the world causing the disease by WHO called COVID-19. This pandemic poses unprecedented stress on the health care system including programs performing allogeneic and autologous hematopoietic cell transplantation (HCT) and cellular therapy such as with CAR T cells. Risk factors for severe disease include age and predisposing conditions such as cancer. The true impact on stem cell transplant and CAR T-cell recipients in unknown. The European Society for Blood and Marrow Transplantation (EBMT) has therefore developed recommendations for transplant programs and physicians caring for these patients. These guidelines were developed by experts from the Infectious Diseases Working Party and have been endorsed by EBMT's scientific council and board. This work intends to provide guidelines for transplant centers, management of transplant candidates and recipients, and donor issues until the COVID-19 pandemic has passed.
Document type :
Journal articles
Complete list of metadata

Cited literature [20 references]  Display  Hide  Download
https://www.hal.inserm.fr/inserm-02747372
Contributor : Myriam Bodescot <>
Submitted on : Wednesday, June 3, 2020 - 11:49:57 AM
Last modification on : Friday, June 4, 2021 - 11:24:21 AM
Long-term archiving on: : Friday, December 4, 2020 - 6:01:54 PM

File

Vignette du document
s41409-020-0919-0.pdf
Publication funded by an institution

Identifiers

Collections

INSERM | UNIV-LILLE | SORBONNE-UNIVERSITE | SU-TI

Citation

Per Ljungman, Malgorzata Mikulska, Rafael de la Camara, Grzegorz Basak, Christian Chabannon, et al.. The Challenge of COVID-19 and Hematopoietic Cell Transplantation; EBMT Recommendations for Management of Hematopoietic Cell Transplant Recipients, Their Donors, and Patients Undergoing CAR T-cell Therapy. Bone Marrow Transplantation, Nature Publishing Group, 2020, ⟨10.1038/s41409-020-0919-0⟩. ⟨inserm-02747372⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

67

Files downloads

185